Currently, the use of MNs in combination with nanomedicine for TDD is limited to proof-of-concept pre-clinical studies, since there has been only one report of a phase 1 clinical trial of human proinsulin peptides coupled to gold NPs delivered intradermally using MNs in type 1 diabetes [331]. Here, INS is linked to type 1 diabetes mellitus.